Clinical trials: Hand Foot Skin Syndrome
Breast Cancer
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or…
- Trial name
- NCT00661102
- Testing
- Corticosteroids, capecitabine [Xeloda], dexpantenol [Bepantol]
- Where
- 35 sites in Brazil
- Volunteers
- 598 people
- Sponsor
- Hoffmann-La Roche
Palmar-plantar Erythrodysesthesia (PPE)
Testing the Effectiveness of Henna on Managing PPE
The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most…
- Trial name
- NCT01751893
- Testing
- Henna
- Where
- Cyprus
- Volunteers
- 56 people
- Sponsor
- Cyprus University of Technology
Capecitabine, Hand-foot Syndrome
Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine.
- Conditions
- Capecitabine, Hand-foot Syndrome, Electroacupuncture, Self-administered Acupressure
- Trial name
- NCT06602167
- Testing
- True electroacupuncture + True self-administered acupressure, Doctor-prescribed treatment
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Qinghai University
Hand-foot Syndrome
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome
A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in patients with early breast cancer.
- Trial name
- NCT05165069
- Testing
- Mecobalamin 5 MG Disintegrating Oral Tablet
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer, Palmar-plantar Erythrodysesthesia
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women receiving doxorubicin hydrochloride liposome for metastatic breast cancer.
- Trial name
- NCT00992706
- Testing
- antiperspirant cream F511, pegylated liposomal doxorubicin hydrochloride
- Where
- 15 sites in Switzerland
- Volunteers
- 91 people
- Sponsor
- Swiss Cancer Institute
Hand Foot Skin Syndrome
Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome
The purpose of this study is to determine whether henna paste is effective in the treatment of hand-foot skin syndrome, induced by the drugs Capecitabine and pegylated liposomal doxorubicin.
- Trial name
- NCT01097850
- Testing
- henna paste
- Sponsor
- Northwestern University
Cancer
The Preventive Effect of Chemotherapy-induced Hand-foot Syndrome
this study will use traditional Chinese medicine bath with no obvious side effects combined with case tracking management mode to form nursing measures to prevent hand foot syndrome.
- Trial name
- NCT06441513
- Testing
- Chinese traditional medicine nursing combined with case tracking management, Health Education
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University Third Hospital
the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine
A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer
The purpose of this study is the examination of Mapisal® versus urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot syndrome (HFS) in patients with gastrointestinal tumors or breast cancer, to assess the…
- Trial name
- PROCAPP (NCT01626781)
- Testing
- Mapisal, Urea hand-foot cream
- Where
- Germany
- Sponsor
- AIO-Studien-gGmbH
Hand-foot Syndrome
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine
Hand-foot syndrome (HFS) is a very common adverse event of many chemotherapeutic agents, especially capecitabine. The HFS can considerably interfere patient quality of life (QoL).
- Trial name
- TACX Care (NCT04833998)
- Testing
- Extremecare
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Hand-Foot Syndrome
Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome
Hand foot skin reaction (HFS) from capecitabine is one of the most common adverse events from capecitabine. Urea cream has been proved its benefit to prevent HFS from sorafenib.
- Trial name
- NCT05348278
- Testing
- Urea cream
- Where
- Thailand
- Volunteers
- 214 people
- Sponsor
- Mahidol University
Hand-foot Syndrome, Hand-foot Skin Reaction
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and/or soles of the feet, which can progress to blistering.
- Trial name
- DermLight (NCT04979078)
- Testing
- Photobiomodulation therapy (PBMT)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Jessa Hospital